反応式
[CH2:1]([O:3][C:4](=[O:13])[CH2:5][C:6](=[O:12])[N:7]1[CH2:11][CH2:10][CH2:9][NH:8]1)[CH3:2].[CH3:14][S:15][C:16]1[N:21]=[C:20]([C:22](O)=[O:23])[CH:19]=[CH:18][N:17]=1.ON1C2C=CC=CC=2N=N1.Cl.CN(C)CCCN=C=NCC.C([O-])(O)=O.[Na+]>CN(C=O)C>[CH2:1]([O:3][C:4](=[O:13])[CH2:5][C:6]([N:7]1[CH2:11][CH2:10][CH2:9][N:8]1[C:22]([C:20]1[CH:19]=[CH:18][N:17]=[C:16]([S:15][CH3:14])[N:21]=1)=[O:23])=[O:12])[CH3:2]参加物
7
反応物 5
生成物 1
試薬・触媒・溶媒 1
実験手順
To a solution of the 3-oxo-3-pyrazolidin-1-yl propionic acid ethyl ester, 11, (8.8 g, 47.7 mmol) in DMF (165 mL) is added 2-methylsulfanyl-pyrimidine-4-carboxylic acid (8.5 g, 50.1 mmol), followed by 1-hydroxybenzotriazole (12.9 g, 95.5 mmol) and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (11.0 g, 57.3 mmol). The reaction mixture is stirred at room temperature for 22 hours then poured into aqueous saturated NaHCO3. The aqueous phase is extracted three times with EtOAc and the combined organic phases are dried (MgSO4), filtered and concentrated in vacuo to afford 10.5 g of the desired compound which is used without further purification.
後処理
- extractionThe aqueous phase is extracted three times with EtOAc
- dry with materialthe combined organic phases are dried (MgSO4)
- filtrationfiltered
- concentrationconcentrated in vacuo
出典と根拠
- ORDレコード
- ord-1de3e9816c604e9bb1c03cc575f2b70e
- 出典データセット
- uspto-grants-2009_01
- 特許番号
- US07482356B2
関連ノート
読み込み中…